FastHeal: A controlled-release dermal dressing for faster diabetes wound recovery

我们建议开发一种新的药物敷料，其中包含一种分子，可以实现更快的糖尿病伤口愈合。这是一个仅在英国就影响到45万糖尿病患者的问题。它每年花费NHS GB 9亿英镑在护理(医疗访问)和治疗费用(抗生素、绷带等)上。我们希望我们的敷料能够在糖尿病压疮形成后实现两倍的伤口愈合速度。这是因为其中包含的分子能够促进受影响伤口处的皮肤上皮组织更快地生长。这可能会导致这种令人衰弱的并发症更快地恢复，并降低感染、败血症和截肢的风险。当压力溃疡形成时，患者可以很容易地将我们的敷料涂在受影响的区域，恢复应该比传统敷料快得多。我们希望通过我们的创新每年为NHS GB节省3.5亿与门诊和初级保健费用相关的成本。来自IVUK的资金将使我们能够开发出一种既能让NHS负担得起，又能代表英国纳税人物有所值的产品。主要受益者将是患有糖尿病和糖尿病并发症的患者，以及已经面临巨大成本和能力压力的NHS。

We propose to develop a novel medicated dressing containing a molecule that achieves faster diabetes wound healing. This is a problem affecting 450,000 individuals with diabetes in the UK alone. It costs the NHS £900M annually in care (healthcare visits) and treatment costs (antibiotics, bandages etc).We expect our dressing to be able to achieve twice as faster wound healing following diabetic pressure ulcers formation. This is because the molecule contained within is capable of encouraging faster growth of epithelial skin tissues at the affected wound site. This could lead to faster recovery from this debilitating complication and less risk for infection, sepsis and amputations. When pressure ulcers develop, patients could easily apply our dressing onto the affected area and recovery should be much quicker than traditional dressings.We expect to save the NHS £350M annually in costs related to out-patient and primary care costs using our innovation. The funding from IVUK will allow us to develop a product that is both affordable to the NHS and represents good value for money for UK taxpayers. The primary beneficiaries will be patients living with diabetes and suffering from its complications as well as NHS which is already under immense cost and capacity pressures.